MYOV

Myovant Sciences Ltd

$16.30

+0.63 (+4.02%)

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

7.67

52 wk hi

27.43

Cash

$434.2M

Burn Rate (Qtr)

$100.1M

Mkt Cap

$1.6b

Avg Volume

708,680

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

MYFEMBREE (Relugolix) (GnRH receptor antagonist)

Uterine fibroids, Uterine disease, Benign tumor

PDUFA

Approval decision

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Relugolix combo tablet (gonadotropin-releasing hormone receptor agonist)

Infertility, Contraceptive, Uterine fibroids

Phase 3

Interim Update

Exp Date

A free account is required to see the catalyst dates, notes, and more!

MVT-602 (oligopeptide kisspeptin-1 receptor agonist)

Infertility

Phase 3

Initiation

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

MYOV

BPIQ_Logo_RGB-01.jpg

Company Profile

We aspire to be the leading healthcare company focused on redefining care for women’s health and prostate cancer. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We strive to improve the lives of millions of people, while building an innovative, dynamic, and collaborative company where employees thrive.

Recent Posts

See what the community is saying - click to see full post.